Stock Analysis
Medpace Holdings, Inc. (MEDP) Stock Analysis
Medpace Holdings, Inc. (MEDP) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Medpace Holdings, Inc. (MEDP) currently has an AIQ Score of 63/100, indicating a neutral setup. Momentum is the strongest factor at 88/100. Value is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MEDP at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $662.48 |
| AIQ Score | 63/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $16.28B |
| P/E Ratio (TTM) | 33.54 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $4.31 |
| Revenue (quarter ended 2026-06-30) | $707.33M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.15 |
| Volume | 1.03M |
| 52-week range | $373.00-$677.90 |
| RSI 14 | 72.47 |
| 50-Day SMA | $608.52 |
| 200-Day SMA | $527.10 |
| Analyst Price Target | $576.06 |
| Next Earnings | — |
MEDPMedpace Holdings, Inc.
Healthcare / Medical - Diagnostics & Research
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum88
- Value30
- Quality79
- Risk resilience55
- Sentiment—
MEDP Stock Analysis Summary
Medpace Holdings, Inc. (MEDP) currently has an AIQ Score of 63/100, indicating a neutral setup. Momentum is the strongest factor at 88/100. Value is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MEDP has AIQ Score of 63/100 with Momentum base of 88/100 and fading Value at 30/100. Wait for component alignment before adding exposure.
Momentum (88/100) leads while Value (30/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 6.43% stock move · MEDP classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MEDP Bullish or Bearish Right Now?
MEDP currently has a neutral overall setup. Momentum is the strongest factor at 88/100, while Value is weakest at 30/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 79/100.
- - Momentum is constructive at 88/100.
- - Price is +8.87% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (38 vs 5).
- - Value is the current constraint at 30/100.
- - Analyst target implies -13.04% downside from the latest quote.
Current Consensus
MEDP's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 2 neutral, and 5 sell votes. MEDP's 14-day RSI is 72.47, which places the stock in an overbought momentum range. MEDP's beta is 1.15, indicating market sensitivity broadly in line with the market.
What Changed in MEDP?
The largest recent change in MEDP is Momentum moving up by 30.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the MEDP Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MEDP Decision Framework
Public evidence layers, setup checks, and risk context for Medpace Holdings, Inc..
Medpace Holdings, Inc. (MEDP) Stock Analysis
Medpace Holdings, Inc. has an AIQ Score of 63/100 in a Neutral regime. Momentum is strongest at 88/100. Beta is 1.18, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MEDP is in a Neutral AIQ regime with score 63/100. |
| Signal Conflict | The primary conflict is that momentum leads at 88/100 while value lags at 30/100. |
| Factor Evidence | Momentum 88/100 · Value 30/100 · Quality 79/100 · Risk 55/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 88/100.
Momentum is 88/100 and RSI (14) is 72.5.
MEDP is in a Neutral regime at 63/100.
Risk factor is 55/100 with beta 1.18 and annual volatility 44.57%.
Current conflict: momentum leads at 88/100 while value lags at 30/100.
MEDP Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MEDP Fundamentals
MEDP valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MEDP Technical Analysis
MEDP technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MEDP Stock Catalysts
Track MEDP earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MEDP Dividend Analysis
MEDP dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MEDP Financial Data
MEDP revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MEDP Risk Analysis
MEDP volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MEDP Stock News
MEDP stock news, market tone, recent headlines, and catalyst context.
MEDP vs Life Sciences / Tools / CRO Peers
Current peer cohort: MEDP · NTRA · PRGO · PTCT · RVTY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MEDP Current stock | 63/100 | 30/100 | 88/100 | 55/100 | 0.59 | 44.57% | Current |
| NTRA Natera | 50/100 | 34/100 | 55/100 | 57/100 | 1.79 | 48.40% | MEDP vs NTRA |
| PRGO Perrigo | 56/100 | 74/100 | 79/100 | 45/100 | -0.34 | 56.29% | MEDP vs PRGO |
| PTCT PTC Therapeutics | 54/100 | 38/100 | 39/100 | 58/100 | -0.11 | 40.62% | MEDP vs PTCT |
| RVTY Revvity | 53/100 | 42/100 | 68/100 | 59/100 | 1.37 | 38.92% | MEDP vs RVTY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts7 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MEDP
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MEDP
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MEDP Stock FAQ
What is MEDP stock price today?
Medpace Holdings, Inc.'s current stock price is $662.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MEDP bullish or bearish right now?
MEDP's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MEDP's market cap?
MEDP's market cap is $16.28B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MEDP's current P/E ratio?
MEDP's current P/E ratio is 33.54 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MEDP's RSI?
MEDP's 14-day RSI is 72.47 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MEDP above its 50-day and 200-day moving averages?
MEDP is 8.87% from its 50-day SMA and 25.68% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MEDP's next earnings date?
MEDP's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MEDP pay a dividend?
MEDP's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.